Download (640 KB)
The University of Texas MD Anderson Cancer Center
Bispecific antibodies, monospecific antibodies, ADCC, programmed death ligand 1
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
CPRIT-CURE Summer Undergraduate Program
Gelin, Ashley; Couillault, Coline Agnes; Srinivasamani, Anupallavi; Liu, Qinying; and Curran, Michael Andrew, "Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC potential and in vivo anti-tumor response" (2021). Summer Experience 2021. 55.